从含有依非韦伦的抗逆转录病毒方案转换为含有多替拉韦的方案时依非韦伦药物遗传学的意义。
Implications of Efavirenz Pharmacogenetics When Switching From Efavirenz- to Dolutegravir-containing Antiretroviral Regimens.
机构信息
Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Department of Internal Medicine, Meharry Medical College, Nashville, Tennessee, USA.
出版信息
Clin Infect Dis. 2021 May 18;72(10):1820-1822. doi: 10.1093/cid/ciaa975.
Abstract
Many patients switch from efavirenz- to dolutegravir-based regimens. In a phase 1 dolutegravir-efavirenz interaction study, mean dolutegravir minimum concentration decreased by 60% and 85% among CYP2B6 normal and slow/intermediate metabolizers, respectively. Mean efavirenz half-life was 2.7 times greater in slow vs normal metabolizers. Slow metabolizers will experience more prolonged subtherapeutic dolutegravir concentrations.
摘要
许多患者从依非韦伦转为多替拉韦方案。在一项多替拉韦-依非韦伦相互作用的 1 期研究中，CYP2B6 正常和慢/中间代谢者的多替拉韦最低浓度分别降低了 60%和 85%。慢代谢者的依非韦伦半衰期比正常代谢者长 2.7 倍。慢代谢者将经历更长时间的治疗浓度不足的多替拉韦。
相似文献
1
Implications of Efavirenz Pharmacogenetics When Switching From Efavirenz- to Dolutegravir-containing Antiretroviral Regimens.从含有依非韦伦的抗逆转录病毒方案转换为含有多替拉韦的方案时依非韦伦药物遗传学的意义。
Clin Infect Dis. 2021 May 18;72(10):1820-1822. doi: 10.1093/cid/ciaa975.
2
CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz.CYP2B6 基因型与多替拉韦和依非韦伦所致体重增加的差异。
Clin Infect Dis. 2021 Dec 6;73(11):e3902-e3909. doi: 10.1093/cid/ciaa1073.
3
Cognitive performance, neuropsychiatric symptoms, and cerebrospinal fluid viral control following programmatic switch from efavirenz-based to dolutegravir-based antiretroviral therapy in South Africa (CONNECT): a prospective cohort study.在南非（CONNECT），从基于依非韦伦的方案转换为基于多替拉韦的抗逆转录病毒治疗后认知功能、神经精神症状和脑脊液病毒控制情况：一项前瞻性队列研究。
Lancet HIV. 2024 Oct;11(10):e680-e689. doi: 10.1016/S2352-3018(24)00209-1. Epub 2024 Sep 13.
4
Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trial.多替拉韦与依非韦伦在晚期妊娠开始抗 HIV 治疗的女性中的应用（DolPHIN-2）：一项开放标签、随机对照试验。
Lancet HIV. 2020 May;7(5):e332-e339. doi: 10.1016/S2352-3018(20)30050-3.
5
Pharmacokinetics of Single-Dose Versus Double-Dose Dolutegravir After Switching From a Failing Efavirenz-Based Regimen.单剂量与双剂量多替拉韦在基于依非韦伦方案失败后转换的药代动力学。
J Acquir Immune Defic Syndr. 2024 May 1;96(1):85-91. doi: 10.1097/QAI.0000000000003402.
6
Pharmacogenetic interactions between antiretroviral drugs and vaginally administered hormonal contraceptives.抗逆转录病毒药物与阴道用激素避孕药之间的药物遗传学相互作用。
Pharmacogenet Genomics. 2020 Apr;30(3):45-53. doi: 10.1097/FPC.0000000000000396.
7
Viremia and HIV Drug Resistance Among People Receiving Dolutegravir Versus Efavirenz-Based First-Line Antiretroviral Therapy.接受多替拉韦与依非韦伦为基础的一线抗反转录病毒治疗的患者中的病毒血症和 HIV 耐药性。
J Acquir Immune Defic Syndr. 2024 Apr 15;95(5):e8-e11. doi: 10.1097/QAI.0000000000003385. Epub 2024 Mar 11.
8
Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study.博茨瓦纳开展的一项观察性研究：在孕期开始使用多替拉韦或依非韦伦为基础的抗逆转录病毒治疗的安全性比较。
Lancet Glob Health. 2018 Jul;6(7):e804-e810. doi: 10.1016/S2214-109X(18)30218-3. Epub 2018 Jun 4.
9
Tryptophan metabolism and its relationship with central nervous system toxicity in people living with HIV switching from efavirenz to dolutegravir.色氨酸代谢及其与从依非韦伦转换为多替拉韦的 HIV 感染者的中枢神经系统毒性的关系。
J Neurovirol. 2019 Feb;25(1):85-90. doi: 10.1007/s13365-018-0688-3. Epub 2018 Nov 26.
10
Risks and Benefits of Dolutegravir- and Efavirenz-Based Strategies for South African Women With HIV of Child-Bearing Potential: A Modeling Study.多替拉韦和依非韦伦方案对有生育潜力的南非 HIV 感染妇女的风险与获益：一项建模研究。
Ann Intern Med. 2019 May 7;170(9):614-625. doi: 10.7326/M18-3358. Epub 2019 Apr 2.
引用本文的文献
1
Change in body weight and risk of hypertension after switching from efavirenz to dolutegravir in adults living with HIV: evidence from routine care in Johannesburg, South Africa.南非约翰内斯堡接受常规治疗的成人艾滋病病毒感染者从依法韦仑换用多替拉韦后体重变化及高血压风险：证据
EClinicalMedicine. 2023 Feb 6;57:101836. doi: 10.1016/j.eclinm.2023.101836. eCollection 2023 Mar.
2
Initial Supplementary Dose of Dolutegravir in Second-Line Antiretroviral Therapy: A Noncomparative, Double-Blind, Randomized Placebo-Controlled Trial.二线抗反转录病毒治疗中的多替拉韦初始补充剂量：一项非比较性、双盲、随机安慰剂对照试验。
Clin Infect Dis. 2023 May 24;76(10):1832-1840. doi: 10.1093/cid/ciad023.
本文引用的文献
1
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy.临床药物遗传学实施联盟（CPIC）指南：CYP2B6 和含依非韦伦的抗逆转录病毒治疗。
Clin Pharmacol Ther. 2019 Oct;106(4):726-733. doi: 10.1002/cpt.1477. Epub 2019 Jul 5.
2
Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial.多替拉韦与利托那韦增强洛匹那韦联合双核苷逆转录酶抑制剂治疗在一线治疗失败的 HIV-1 感染成人中的疗效（DAWNING）：一项开放标签、非劣效性、3b 期临床试验。
Lancet Infect Dis. 2019 Mar;19(3):253-264. doi: 10.1016/S1473-3099(19)30036-2. Epub 2019 Feb 4.
3
The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: what are the issues?向低收入和中等收入国家中的地拉韦啶和其他新型抗逆转录病毒药物的转换：存在哪些问题？
AIDS. 2018 Jul 31;32(12):1551-1561. doi: 10.1097/QAD.0000000000001845.
4
Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial.多替拉韦钠单药维持治疗与拉米夫定联合治疗：DOLAM 随机临床试验的 24 周计划分析。
J Antimicrob Chemother. 2018 Jul 1;73(7):1965-1971. doi: 10.1093/jac/dky093.
5
Dolutegravir as maintenance monotherapy for HIV (DOMONO): a phase 2, randomised non-inferiority trial.多替拉韦作为 HIV 的维持单药治疗（DOMONO）：一项 2 期、随机、非劣效性试验。
Lancet HIV. 2017 Dec;4(12):e547-e554. doi: 10.1016/S2352-3018(17)30152-2. Epub 2017 Oct 26.
6
Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study.多替拉韦/阿巴卡韦/拉米夫定与当前抗逆转录病毒疗法用于病毒学抑制患者的比较（STRIIVING）：一项48周的随机、非劣效性、开放标签的IIIb期研究。
Antivir Ther. 2017;22(4):295-305. doi: 10.3851/IMP3166. Epub 2017 Apr 12.
7
Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir.依非韦伦和替拉那韦/ritonavir 对 HIV 整合酶抑制剂多替拉韦的药代动力学的影响。
Eur J Clin Pharmacol. 2014 Oct;70(10):1173-9. doi: 10.1007/s00228-014-1732-8. Epub 2014 Aug 23.
8
Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants.全基因组关联研究发现 AIDS 临床试验组方案中血浆依非韦伦药代动力学与几个 CYP2B6 变异有关。
Pharmacogenet Genomics. 2012 Dec;22(12):858-67. doi: 10.1097/FPC.0b013e32835a450b.
9
Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial.每日一次多替拉韦（S/GSK1349572）联合治疗方案用于初治 HIV 成人：SPRING-1 剂量范围、随机、2b 期试验的 48 周计划中期结果。
Lancet Infect Dis. 2012 Feb;12(2):111-8. doi: 10.1016/S1473-3099(11)70290-0. Epub 2011 Oct 20.
Zotero 插件